- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03319940
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
June 11, 2024 updated by: Amgen
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, ascending, multiple doses, phase 1 study evaluating tarlatamab monotherapy, in combination with anti-PD1 therapy and with additional cytokine release syndrome (CRS) mitigation strategies.
Tarlatamab will be administered as a short term intravenous (IV) infusion in participants with SCLC.
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
Study Type
Interventional
Enrollment (Estimated)
392
Phase
- Phase 1
Expanded Access
Available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Recruiting
- Chris OBrien Lifehouse
-
-
-
-
-
Graz, Austria, 8036
- Recruiting
- Medizinische Universitaet Graz
-
Salzburg, Austria, 5020
- Terminated
- Landeskrankenhaus Salzburg
-
-
-
-
-
Villejuif, France, 94805
- Recruiting
- Gustave Roussy
-
-
-
-
-
Wuerzburg, Germany, 97078
- Recruiting
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Shatin, New Territories, Hong Kong
- Recruiting
- Prince of Wales Hospital
-
-
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Recruiting
- National Cancer Center Hospital East
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- Recruiting
- National Cancer Center Hospital
-
-
Wakayama
-
Wakayama-shi, Wakayama, Japan, 641-8510
- Recruiting
- Wakayama Medical University Hospital
-
-
-
-
-
Amsterdam, Netherlands, 1066 CX
- Recruiting
- Nederlands Kanker Instituut Antoni van Leeuwenhoekziekenhuis
-
Maastricht, Netherlands, 6229 HX
- Completed
- Maastricht Universitair Medisch Centrum
-
-
-
-
-
Jozefow, Poland, 05-410
- Recruiting
- Biokinetica SA
-
Otwock, Poland, 05-400
- Recruiting
- Europejskie Centrum Zdrowia Otwock Szpital imienia Fryderyka Chopina
-
-
-
-
-
Madrid, Spain, 28034
- Recruiting
- Hospital Universitario Ramon y Cajal
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz
-
-
Cataluña
-
Barcelona, Cataluña, Spain, 08035
- Recruiting
- Hospital Universitari Vall d Hebron
-
Barcelona, Cataluña, Spain, 08036
- Recruiting
- Hospital Clinic i Provincial de Barcelona
-
-
-
-
-
Lausanne, Switzerland, 1011
- Recruiting
- Centre Hospitalier Universitaire Vaudois
-
Sankt Gallen, Switzerland, 9007
- Recruiting
- Kantonsspital St Gallen
-
-
-
-
-
Kaohsiung, Taiwan, 80756
- Recruiting
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Taipei, Taiwan, 11490
- Recruiting
- Tri-Service General Hospital
-
Taoyuan, Taiwan, 33305
- Recruiting
- Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
-
-
-
-
-
Manchester, United Kingdom, M20 4BX
- Recruiting
- Christie Hospital
-
-
-
-
California
-
Duarte, California, United States, 91010
- Completed
- City of Hope National Medical Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale New Haven Hospital
-
-
Florida
-
Tampa, Florida, United States, 33612
- Terminated
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Recruiting
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- John Hopkins Sidney Kimmel Comprehensive Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health System
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110-1093
- Recruiting
- Washington University
-
-
New York
-
New York, New York, United States, 10021
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospitals Cleveland Medical Center
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Recruiting
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15232
- Terminated
- University of Pittsburgh Medical Center Cancer Pavillion
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participant has provided informed consent prior to initiation of any study-specific activities/procedures
- Age greater than or equal to 18 years old at the time of signing the informed consent
- Histologically or cytologically confirmed SCLC. For parts A, C, D, E, F, and G: relapsed/refractory small cell lung cancer (R/R SCLC) who progressed or recurred following platinum-based regimen
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Participants with treated brain metastases are eligible provided they meet defined criteria
- Adequate organ function as defined in protocol
Exclusion Criteria:
- History of other malignancy within the past 2 years prior to first dose of tarlatamab with exceptions
- Major surgery within 28 days of first dose tarlatamab
- Untreated (includes new lesions or progression in previously treated lesions) or symptomatic brain metastases and leptomeningeal disease (regardless of symptomatic or not).
- Prior anti-cancer therapy: at least 28 days must have elapsed between any prior anti-cancer therapy and first dose of tarlatamab with the following exceptions: participants who received conventional chemotherapy are eligible if at least 14 days have elapsed and if all treatment-related toxicity has been resolved to Grade less than or equal to 1; and prior palliative radiotherapy must have been completed at least 7 days before the first dose of tarlatamab
- Participants who experienced severe, life-threatening or recurrent (Grade 2 or higher) immune-mediated AEs or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immune-oncology agents
- Has evidence of interstitial lung disease or active, non-infectious pneumonitis
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of tarlatamab
- Part C only: history of solid organ transplantation or active autoimmune disease that has required systemic treatment within the past 2 years
- Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of investigational product administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A
Tarlatamab monotherapy
|
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
|
Experimental: Part C
Tarlatamab with Pembrolizumab
|
Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
|
Experimental: Part D
Tarlatamab with additional CRS mitigation strategies
|
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
Participants will be treated with one of the CRS mitigation strategies.
|
Experimental: Part E
Tarlatamab administration with 24-hour monitoring
|
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
|
Experimental: Part F
Tarlatamab administered in outpatient infusion centers with 8-hour monitoring Optional wearable digital device substudy (US sites only) |
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
|
Experimental: Part G
Tarlatamab additional dosing schedule Optional wearable digital device substudy (US sites only) |
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with dose limiting toxicities (DLT) for all indications
Time Frame: 6 months
|
6 months
|
Number of participants with treatment-emergent adverse events (AEs) for all indications
Time Frame: 4 years
|
4 years
|
Number of participants with treatment-related AEs for all indications
Time Frame: 4 years
|
4 years
|
Number of participants with clinically significant changes in vital signs for all indications
Time Frame: 4 years
|
4 years
|
Number of participants with significant changes in electrocardiogram (ECG) for all indications
Time Frame: 4 years
|
4 years
|
Number of participants with significant changes in physical examinations for all indications
Time Frame: 4 years
|
4 years
|
Number of participants with significant changes in clinical laboratory tests for all indications
Time Frame: 4 years
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
9-month Progression-Free Survival (PFS) for all indications
Time Frame: 9 months
|
9 months
|
|
9-month Overall Survival (OS) for all indications
Time Frame: 9 months
|
9 months
|
|
Maximum observed concentration (Cmax) following intravenous administration for all indications
Time Frame: 4 years
|
4 years
|
|
Minimum observed concentration (Cmin) following intravenous administration for all indications
Time Frame: 4 years
|
4 years
|
|
Area under the concentration-time curve (AUC) over the 2 week dosing interval for all indications
Time Frame: 4 years
|
4 years
|
|
Accumulation following multiple dosing for all indications
Time Frame: 4 years
|
4 years
|
|
Half-life (t1/2) following intravenous administration for all indications
Time Frame: 4 years
|
4 years
|
|
Objective Response (OR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Time Frame: 4 years
|
Only for parts A, D, E, F, and G
|
4 years
|
Duration of Response (DOR) for all indications
Time Frame: 4 years
|
4 years
|
|
Time to Response (TTR)
Time Frame: 4 years
|
4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 26, 2017
Primary Completion (Estimated)
October 18, 2024
Study Completion (Estimated)
October 18, 2025
Study Registration Dates
First Submitted
October 5, 2017
First Submitted That Met QC Criteria
October 19, 2017
First Posted (Actual)
October 24, 2017
Study Record Updates
Last Update Posted (Actual)
June 13, 2024
Last Update Submitted That Met QC Criteria
June 11, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- 20160323
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD Sharing Time Frame
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities.
There is no end date for eligibility to submit a data sharing request for this study.
IPD Sharing Access Criteria
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s).
In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling.
Requests are reviewed by a committee of internal advisors.
If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision.
Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.
This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications.
Further details are available at the URL below.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Carcinoma
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell CarcinomaUnited States
Clinical Trials on Pembrolizumab
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsRecruitingColorectal Cancer | Endometrium CancerNetherlands
-
Michael BoyiadzisMerck Sharp & Dohme LLCCompletedAcute Myeloid LeukemiaUnited States
-
University of UtahMerck Sharp & Dohme LLCTerminatedNeuroendocrine TumorsUnited States
-
The University of Hong KongMerck Sharp & Dohme LLCUnknown